Tyrosine Kinase Inhibitors - Pipeline Insights 2017

The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and EMA designations. It also assesses the pipeline tyrosine kinase inhibitors by monotherapy, combination products, molecule type and route of administration. In addition to analysis on active pipeline molecules, the report also provides detailed information about discontinued and dormant drugs.

The report profiles key players in developing potential tyrosine kinase drug candidates. The company profile section provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

Scope

Provides in-depth insights about active Tyrosine kinase inhibitors pipeline drug candidates

Offers an extensive pipeline product coverage with demarcation by various stages of development from NDA filings to discovery

Provides pipeline assessment by monotherapy, combination therapy products, and route of administration

Provides comparative analysis of key marketed and pipeline Tyrosine kinase inhibitors

Includes coverage of detailed pipeline drug profiles, which include product description, chemical information, MOA, licensors and collaborators, development partner

Analyzes key players involved in clinical research and development of the Tyrosine Kinase inhibitors

Provides the coverage of key news related to Tyrosine kinase inhibitors, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

Tyrosine kinases are a subclass of protein kinase. Tyrosine kinases play a central role in signal transduction that ultimately affects gene transcription within the nucleus. These molecules are considered as pivotal points of functional cellular pathways as they control cell cycle, proliferation, differentiation, and cell death or survival. Tyrosine kinases are primarily classified as receptor tyrosine kinase (RTK) which inlcude EGFR, PDGFR, FGFR and the IR and non-receptor tyrosine kinase (NRTK) which include SRC, ABL, FAK and Janus kinase. Disruption in tyrosine kinase pathway is implicated in several malignancies and thus tyrosine kinase inhibitors, targeted drug molecules inhibiting tyrosine kinase activity, are considered as a key therapeutic class. Few of the key marketed tyrosine kinase inhibitors include Dasatinib (Sprycel), Erlotinib (Tarceva), Gefitinib (Iressa), Imatinib (Gleevec). Lapatinib (Tykerb), Nilotinib (Tasigna), Sorafenib (Nexavar), Sunitinib (Sutent).

Over the past two decades, research studies have proved its efficacy for mitigation and control of non-cancerous diseases too. Thus research activity on use of inhibitors for various diseases such as Parkinson's disease and chronic obstructive pulmonary disorder is gradually increasing. The growing availability of these agents has enabled the pharmaceutical companies to develop new combination molecules which have the capacity to provide greater insight into the body’s acceptance of inhibitors so as to develop more effective therapies.

More recently, few molecules have been developed that inhibits tyrosine kinase these agents are in various stages of clinical development. The tyrosine kinase inhibitors pipeline has more than 15 molecules and is expected to achieve the regulatory approval in the near future, few of which are Oncoprex (CNVN202), ORS-1006, JNJ 49095397, RV-568, AP32788, APTO-500, and transtinib. In pipeline analysis, these are analyzed on the basis of route of administration (ROA) and type of molecule. The pipeline is also assessed based on monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-Clinical stage. Few of the companies which are involved in the development of tyrosine kinase inhibitor include IL-Yang Pharm, SRI, Sareum, Genprex, Arrien, J&J, and Takeda.

Reasons to Buy

To gain erudite insights about the Tyrosine Kinase inhibitor pipeline landscape

To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine

To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market

To identify competitors and design strategic initiatives for drug development activities

To understand the market and choose right partners for strategic collaborations

To obtain informed updates on drug termination/drug discontinuation

Related Reports

1) Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Pipeline Insights 2017

https://www.arizton.com/reports/pharma-pipeline-analysis/chimeric-antigen-receptor-car-t-cell-immunotherapy-pipeline-insights-2017

2) Bruton's Tyrosine Kinase (BTK) Inhibitors - Pipeline Insights 2017

https://www.arizton.com/reports/pharma-pipeline-analysis/brutons-tyrosine-kinase-btk-inhibitors-pipeline

About Arizton
Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Mail: enquiry@arizton.com
Call: +1-312-465-7864

This release was published on openPR.